← Back to headlines
JPMorgan Reiterates Rating on Ionis Pharmaceuticals Based on Dosing Advantage
JPMorgan maintained its existing investment rating on Ionis Pharmaceuticals, citing the company's dosing regimen advantages and positive outlook for its therapeutic pipeline.
31 Aug, 07:32 — 31 Aug, 07:32
Sources
Showing 1 of 1 sources
Related Stories
South Korean Video Game Tycoon Ordered to Pay Record Divorce Settlement
32m ago
Chinese AI Firm DeepSeek Prepares for Domestic IPO With Citic Securities as Underwriter
37m ago
Samsung Chairman Lee to Acquire Major Stake From His Mother
40m ago
Covenant unveils low-cost cruise missile with plans for Leipzig factory
41m ago